UNITED STATESSECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-KCURRENT REPORT

Pursuant to Section 13 or 15(d) ofThe Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2018

Glaukos Corporation(Exact name of registrant as specified in its charter)

Delaware 001-37463 33-0945406(State or other jurisdiction (Commission (I.R.S. Employer

of incorporation) File Number) Identification No.)

229 Avenida Fabricante San Clemente, California

92672

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (949) 367-9600

Not Applicable(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of theregistrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of theSecurities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of thischapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct. ☐ 

 

Item 1.01. Entry into a Material Definitive Agreement.

On November 14, 2018, Glaukos Corporation (the “Company”) entered into an Office Building Lease dated as of November14, 2018 (the “Lease”), between the Company and CIP 2014/SG, Aliso Owner LLC (“Landlord”), pursuant to which theCompany will lease three existing office buildings, comprising approximately 160,000 rentable square feet of space, locatedin Aliso Viejo, California (the “Aliso Facility”). The term of the Lease will commence on May 1, 2019 and continue for 13years. The Company intends to relocate its corporate administrative headquarters, along with certain laboratory, R&D andwarehouse space, to the Aliso Facility. The Company currently intends to maintain its manufacturing facilities at its SanClemente location for the foreseeable future.

Under the terms of the Lease, the Company’s rent will be abated for 16 months. The Company will also receive an allowancefrom the Landlord to be applied to the Company’s construction of tenant improvements at the Aliso Facility following thecommencement date of the Lease. The effectiveness of this Lease is contingent upon the Company’s purchase of certainundeveloped land located adjacent to the Aliso Facility.

The description above of the terms of the Lease is subject in its entirety to the terms of the Lease, which will be attached as anexhibit to the Company’s Annual Report on Form 10-K that will be filed with the U.S. Securities and Exchange Commissionfor the year ending December 31, 2018.

Item 7.01. Regulation FD Disclosure.

Glaukos Corporation (the “Company”) intends to present the materials attached as Exhibit 99.1 to this Current Report onForm 8-K (the “Investor Presentation”) from time to time in presentations to investors and other stakeholders. The InvestorPresentation will also be available on the investor page of the Company’s website at http://investors.glaukos.com.

The information contained in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of theSecurities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and is notincorporated by reference into any filing of the Company whether made before or after the date hereof, regardless of anygeneral incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits .

Exhibit No. Description99.1 Investor Presentation, dated November 2018

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to besigned on its behalf by the undersigned hereunto duly authorized.

GLAUKOS CORPORATION (Registrant)

By: /s/ Joseph E. Gilliam Name: Joseph E. Gilliam Title: Chief Financial Officer and Senior Vice

President, Corporate Development Date: November 16, 2018

Exhibit 99.1

1©2018GlaukosCorporation1November2018

2©2018GlaukosCorporationAllstatementsotherthanstatementsofhistoricalfactsincludedinthispresentationthataddressactivities,eventsordevelopmentsthatweexpect,believeoranticipatewillormayoccurinthefutureareforward-lookingstatements.Althoughwebelievethatwehaveareasonablebasisforforward-lookingstatementscontainedherein,wecautionyouthattheyarebasedoncurrentexpectationsaboutfutureeventsaffectingusandaresubjecttorisks,uncertaintiesandfactorsrelatingtoouroperationsandbusinessenvironment,allofwhicharedifficulttopredictandmanyofwhicharebeyondourcontrol,thatmaycauseouractualresultstodiffermateriallyfromthoseexpressedorimpliedbyforward-lookingstatementsinthispresentation.Thesepotentialrisksanduncertaintiesinclude,withoutlimitation,uncertaintiesaboutourabilitytomaintainprofitability;ourdependenceonthesuccessandmarketacceptanceoftheiStent®;ourabilitytoleverageoursalesandmarketinginfrastructuretoincreasemarketpenetrationandacceptancebothintheUnitedStatesandinternationallyofourproducts;ourdependenceonalimitednumberofthird-partysuppliers,someofwhicharesingle-source,forcomponentsofourproducts;theoccurrenceofacripplingaccident,naturaldisasterorotherdisruptionatourprimaryfacility,whichmaymateriallyaffectourmanufacturingcapacityandoperations;maintainingadequatecoverageorreimbursementbythird-partypayorsforproceduresusingtheiStentorotherproductsindevelopment;ourabilitytoproperlytrain,andgainacceptanceandtrustfrom,ophthalmicsurgeonsintheuseofourproducts;ourabilitytosuccessfullydevelopandcommercializeadditionalproducts;ourabilitytocompeteeffectivelyinthehighlycompetitiveandrapidlychangingmedicaldeviceindustryandagainstcurrentandfuturecompetitors(includingMIGScompetitors)thatarelargepubliccompaniesordivisionsofpubliclytradedcompaniesthathavecompetitiveadvantages;thetiming,effectandexpenseofnavigatingdifferentregulatoryapprovalprocessesaswedevelopadditionalproductsandpenetrateforeignmarkets;theimpactofanyproductliabilityclaimsagainstusandanyrelatedlitigation;theeffectoftheextensiveandincreasingfederalandstateregulationinthehealthcareindustryonusandoursuppliers;thelengthyandexpensiveclinicaltrialprocessandtheuncertaintyofoutcomesfromanyparticularclinicaltrial;ourabilitytoprotect,andtheexpenseandtime-consumingnatureofprotecting,ourintellectualpropertyagainstthirdpartiesandcompetitorsthatcoulddevelopandcommercializesimilaroridenticalproducts;theimpactofanyclaimsagainstusofinfringementormisappropriationofthirdpartyintellectualpropertyrightsandanyrelatedlitigation;andthemarket’sperceptionofourlimitedoperatinghistoryasapubliccompany.Theseandotherknownrisks,uncertaintiesandfactorsaredescribedindetailunderthecaption“RiskFactors”andelsewhereinourfilingswiththeSecuritiesandExchangeCommission,includingourAnnualReportonForm10-Kfor2017andQuarterlyReportonForm10-QforthequarterendedSeptember30,2018.OurfilingswiththeSecuritiesandExchangeCommissionareavailableintheInvestorSectionofourwebsiteatwww.glaukos.comoratwww.sec.gov.Inaddition,informationabouttherisksandbenefitsofourproductsisavailableonourwebsiteatwww.glaukos.gov.Allforward-lookingstatementsincludedinthispressreleaseareexpresslyqualifiedintheirentiretybytheforegoingcautionarystatements.Youarecautionednottoplaceunduerelianceontheforward-lookingstatementsinthispressrelease,whichspeakonlyasofthedatehereof.Wedonotundertakeanyobligationtoupdate,amendorclarifytheseforward-lookingstatementswhetherasaresultofnewinformation,futureeventsorotherwise,exceptasmayberequiredunderapplicablesecuritieslaw.Disclaimer

3©2018GlaukosCorporationWearetransformingglaucomatherapy…OURMISSIONTODAYTopioneerandleadtheglobalglaucomamarketwithmicro-scaleinjectabletherapiesthatadvancethestandard-of-careandenrichthelivesandtreatmentalternativesforglaucomapatientsworldwide.OURLONG-TERMSTRATEGICGOALToleadtheglobalophthalmicmarketforwardbybuildingrobustsustainedpharmaceutical,surgicalanddiagnosticplatformsthatprovidedrop-lessapproachesforeffectivelymanagingglaucomaandotheroculardiseases.…andtransformingGlaukosintoanophthalmicpharma/deviceleader.OurMissionandLong-termGoal

4©2018GlaukosCorporation2018KeyObjectivesDrivingMIGStowardstheglobalstandardofcarewhileadvancingatransformationalfutureObtainFDAapprovalandcommenceUScommerciallaunchofiStentinject®BeginpatientenrollmentofkeypivotalstudiesDriveincreasedpenetrationinourinternationalmarketsExpandourpharmaceuticalcapabilitiesthroughcontinuedinvestment

5©2018GlaukosCorporation2013201420152016TotalNetSales(inmillions)86%Q32018GrossMargin$138MCash&Short-TermEquivalents**Asof9/30/2018DemonstratedFinancialPerformance21.045.671.7114.4159.32018201740.143.243.9Q3Q1Q24-YrCAGR:66%

6©2018GlaukosCorporationMIGSANDBEYONDDeliveringNovelSurgical&PharmaceuticalGlaucomaTherapy

7©2018GlaukosCorporationOcularHypertensionIOPof21-30mmHgTargetIOP20%↓frombaseline;≤18mmHgTreatment0-1medMildOAGIOPof25-30mmHgwithminoropticnervedamageandvisualfieldlossModerateOAGIOPof>30mmHgwithmoderateopticnervedamageandvisualfieldlossAdvancedOAGUncontrolledIOPwithsignificantopticnervedamageandvisualfieldlossRefractoryOAGUncontrolledIOPwithsevereopticnervedamageandvisualfieldlossIOPismeasuredinmillimetersofmercury(mmHg).NormalIOPinhealthyeyesrangesfrom10-21mmHg.CurrentOAGTreatmentAlgorithm12345Open-AngleGlaucomaProgressionTargetIOP25%↓frombaseline;≤18mmHgTreatment~1med,laser,MIGSTargetIOP30%↓frombaseline;≤15mmHgTreatment~2meds,laser,MIGSTargetIOP35%↓frombaseline;<15mmHgTreatment~3meds,filteringsurgery,tubeshuntTargetIOP35%↓frombaseline;<15mmHg(ideally~12mmHg)Treatment3+meds,filteringsurgery,tubeshunt

8©2018GlaukosCorporationOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYAddressingfullrangeofglaucomadiseasestatesandprogressionInjectabledrugdeliveryimplant;sustaineddrugtherapyforextendedperiodsEnvisionusealoneorincombinationwithotherMIGSdevicesInjectable2-stenttherapyforstandaloneproceduresInjectable2-stenttherapyforcombo-cataractproceduresAccessessecondaryoutflowpathway;envisionuseprimarilyincombinationwithotherMIGSdevicesInjectable3-stenttherapyforstandaloneproceduresPortfolioofMicro-ScaleInjectableTherapyREFRACTORYADVANCEDMODERATEMILDOCULARHYPERTENSIONSinglestenttherapyforcombo-cataractproceduresTMTM®iStentSA,iStentSupra,iStentinfiniteandiDosearenotapprovedbytheFDA.

9©2018GlaukosCorporationOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORY2021-22201820202020-215in5:EstimatedCadenceofMajorNewU.S.ProductIntroductionsREFRACTORYADVANCEDMODERATEMILDOCULARHYPERTENSION2023iStentSA,iStentSupra,iStentinfiniteandiDosearenotapprovedbytheFDA.AddressingfullrangeofglaucomadiseasestatesandprogressionTMTM2012®

10©2018GlaukosCorporationDrugReservoirScleralAnchorRetainingCapElutionMembraneTitaniumimplant(1.8mmx0.5mm)designedforcontinuousdrugdeliverydirectlyintoanteriorchamberFilledwithproprietary,novelanduber-potentformulationoftravoprost;membrane-controlledFickianelution;zero-orderratesdemonstratedinvitroandinvivoElegantandfacileinjectableprocedure;bypassingcorneaallowsformicro-elutionratestoachievetherapeuticindexAnchorkeepsdeviceinplaceandfacilitatesstraightforwardexchangeupondrugdepletionOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYiDoseTMTravoprost:First-of-a-KindIntraocularDrugDeliveryDeviceTMiDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluse

11©2018GlaukosCorporationiDoseTMTravoprostUSPhaseII:PreliminaryEfficacyResultsAverageIOPreductionsthroughMonth12rangingfrom7.9to8.5mmHgintheimplantarmsRepresents32-33%reductionintheimplantarmsAverageIOPReductionsfromBaselinethroughMonth12*FastElutionSlowElution*CalculatedusingallIOPobservationsthrougheachdatapointweightedequallymmHgTimolol0.5%8.58.48.48.28.08.07.97.97.67.67.67.66.06.57.07.58.08.59.0Week12Month6Month9Month1233%30%n=51544950534935424025242532%33%33%32%32%32%32%30%30%30%iDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluse

12©2018GlaukosCorporationiDoseTMTravoprostUSPhaseII:PreliminaryEfficacyResultsMeanNumberofMedicationsFastElutionSlowElutionTimolol0.5%n=515449505349354240252425iDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluse0.220.400.510.560.190.340.430.540.330.430.580.720.000.100.200.300.400.500.600.700.800.901.00Week12Month6Month9Month12MeannumberofmedsatMonth12were0.56and0.54fortheimplantarmsFavorablesafetyprofilewithnohyperemiareportedineitherimplantarm

13©2018GlaukosCorporationiDoseTMTravoprost:Micro-ScaleRxInjectableTherapyiDoseClinicalGoalsToachievenon-inferiorityIOPreduction(comparableresults)toexistingtopicalglaucomatherapiesToprovideamaximaltherapeuticperiodofIOPcontrol(minimumof6months)TominimizesideeffectsandadverseeventsMedicalNeedsAddresshighratesofpatientnon-adherencewithtopicalglaucomaregimensProvidesufficientdurationofeffectwithfavorableriskprofileiDoseRegulatoryStatusUSINDPhaseIIItrialunderwaySeekingapprovalinEuropeanmarketsandJapanProstaglandinsBetaBlockersAlphaAgonistsCombinationDrugsOther53%Prostaglandinanalogsaremostcommonfirst-linemedicationformanagementofIOP“Inclinicaltrials…TravatanorTravatanZdosedoncedailyintheeveningdemonstrated7-8mmHgreductionsinIOP”TravatanZpackageinsertiDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluse

14©2018GlaukosCorporationiDoseTMTravoprostProcedureiDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluse

15©2018GlaukosCorporationiDoseTMTravoprostExchange(Removal)ProcedureiDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluse

16©2018GlaukosCorporationFDAapprovedin2018Twoheparin-coatedtitaniumtrabecularbypassstents,eachprovidingmulti-directionalflowAuto-injectioninserterallowssurgeontopreciselyimplantstentsthroughsinglecornealentrypointinstraightforward,click-and-releasemotionCombination-CataractTherapyforMildtoModerateOAGOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYiStentSupraisnotapprovedbytheFDA4mmimplant,curvedtofollowocularanatomyLumensizedforoptimalflowandminimaltraumaHeparin-coatedinter-lumendesignedtoaidflowOutletlocationoptimizedtomaximizeflowwithminimalencapsulationpotentialFDAapprovedin2012;flagshipMIGSdeviceHeparin-coatedstent,pre-loadedininserterErgonomicraildesignprotectsandaccessesunderlyingcollectorchannelsinSchlemm’scanal;retentionarcheshelpensuresecureplacement

17©2018GlaukosCorporationReal-WorldClinicalExperienceofSingleiStent®withCataractSurgeryCaseseriesshowed16%reductioninmeanmedicatedIOP;aftermeanfollow-upof54months,42%ofpatientsweremedicationfreeArriola-VillalobosPetalBritishJournalofOphthalmology2012MeanIOPmmHg19.417.416.115.916.516.116.3121620Preop(n=19)Year1(n=19)Year2(n=19)Year3(n=19)Year4(n=16)Year5(n=13)Final(n=19)Medicationfreeat54months42%MeanIOPmmHg19.316.415.716.416.315.212162024Preop(n=107)1M(n=102)6M(n=82)12M(n=98)18M(n=77)24M(n=107)Reductioninmean#ofmeds56%Consistentcohortof107OAGeyesfollowedthrough2yearsachievedmeanIOPreductionof22%and56%reductioninmeanmedicationsFergusonJBerdahlJClinicalOphthalmology2016

18©2018GlaukosCorporationSamuelsonT,ASCRS2018iStentinject®MeetsPrimaryandSecondaryPivotalTrialEndpointsProspectivetrialwith41sitesand505OAGsubjects387subjectsrandomizedtoiStentinjectincombinationwithcataractsurgery118subjectsrandomizedtocataractsurgeryonlySubjectsfollowedthrough24monthswithannualmedicationwashouts75.8%61.9%≥20%ReductioninUnmedicatedIOP∆=13.9%P=0.0037.05.4MeanUnmedicatedIOPReduction(mmHg)∆=1.6mmHgP<0.001PhacoAloneiStentinject+Phaco•17.1mmHgunmedicatedmeanIOPat24M,a31%meanreductionfromunmedicatedmeanbaselineof24.8mmHg•75%reductioninmean#ofmeds,representinga50%ormorereductionvs.controlgroupat23MAdditionalobserveddatashowed:iStentinject+cataractcohortdemonstratedexcellentsafetyprofile,similartocataractonly

19©2018GlaukosCorporation26Peer-ReviewedPublicationsoniStentinject®orMultipleiStent®TherapyConsecutivecaseseriesstudyinprimarilyOAGeyes;81implantedwithiStentinjectincombinationwithcataractsurgeryHengererF.ASCRS2018MeanIOPmmHg22.614.814.514.31216202428Preop(n=81)Year1(n=71)Year2(n=52)Year3(n=41)Reductioninmean#ofmeds68%Retrospective,single-sitecaseseriesof179eyeswithvaryingglaucomaseverityandconcomitantcataractsurgeryHarasymowycz,P.ASCRS2018MeanIOPmmHg16.213.8101418Preop6months-1yearReductioninmean#ofmeds43%7450204060PreopPostop%MedicationFreeiStentinject®+CataractSurgeryiStentinject®+CataractSurgery

20©2018GlaukosCorporationFacile,Click-and-Release2-StentProcedure

21©2018GlaukosCorporationMIGSStandaloneSolutionforAdvancedandRefractoryOAGThreeheparin-coatedtrabecularbypassstents,preloadedintoautoinjectionsystemEnhancedinsertionsystemprovidesunlimitedactivationsandsmoothimplantationofeachstentacross5-6clockhoursofSchlemm’scanalLessinvasive,fasterrecoveryandfewercomplicationsthanconventionallate-stageprocedures;noblebformationOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYiStentinfiniteisnotapprovedbytheFDATitratableStentTherapyMeanIOPmmHg17.415.814.21014182226MeanpreopmedicatedIOPMeanpreopIOPafterwashoutMonth36-37post-washoutIOP1Stent2Stent3StentInternationalstudyofOAGpatients(n=119)withunmedicatedIOPof22-38mmHg;randomizedtoreceive1,2or3stentsinstandaloneprocedure;follow-uptocontinuefor5yearsKatzLJetalClinicalOphthalmology2018TM

22©2018GlaukosCorporationMIGSStandaloneSolutionforAdvancedandRefractoryOAGiStentinfiniteisnotapprovedbytheFDA

23©2018GlaukosCorporationTwoheparin-coatedtitaniumstents,preloadedintoautoinjectionsystemTaperedinsertionsleeveyieldssmoothinsertionduringclosed-chamberprocedureinpseudophakicpatientsAbilitytoentertheeyeoncetoimplantbothstentsinstraightforwardclick-and-releasemotionStandalone2-StentTherapyforMildtoModerateOAGOAGProgressionOCULARHYPERTENSIONMILDMODERATEADVANCEDREFRACTORYiStentSAisnotapprovedbytheFDA2StandaloneStents19.524.414.314.214.113.113.21014182226PreopBaseline(Washout)Month1Month12Month24Month36Month42International,prospectivestudy;allpatients(n=57)on1preoperativeglaucomamedication;at42M,95%ofeyesremainedmedicationfreeLindstromRASCRS2018mmHg®

24©2018GlaukosCorporationAlconCyPassTM•6.35mmpolyimideshuntimplantedabinternointosuprachoroidalspace•ApprovedbyFDAin2016forcombo-cataractprocedures;voluntarilywithdrawnfrommarketin2018IvantisHydrusTM•8mmnitinoldeviceimplantedabinternointoSchlemm’scanal•ApprovedbyFDAin2018forcombo-cataractprocedures•ManualrotaryinsertionXENMarketLeaderwithMarket-ExpandingPipelinevs.Single-ProductCompetitorsMildtoModerateRefractoryAllerganXENTM•6mmcollagenshuntimplantedabinternointosubconjunctivalspace•Createsbleb;requiresuseofantimetabolite•ApprovedbyFDAin2016forcombo-cataractorstandaloneproceduresiStentiStentInjectCyPassHydrusXENiStentSupra

25©2018GlaukosCorporationPotentiallyExpandingOurAnnualMarketOpportunity7x+OHT/POAGprevalence:~18Meyes8.2MeyesdiagnosedandtreatedGrowing3.5%annually33%ofstandaloneOHT/POAGpopulationispseudophakicCombinationtherapydrivesmoreopportunityforGlaukosportfolio*2017marketopportunity;basedonGlaukosalgorithmofphysicianpreferenceandcombinationtherapyutilization;assumesfullproductportfolioavailabilityforphysician2xTotalglobalopportunityUSAnnualOpportunity*(eyes)Mild-ModPOAG/Combo-cataractAdv-RefractoryPOAG/StandaloneMild-ModPOAG/StandaloneOHT-RefractoryPOAG/Standalone~0.6M~0.8M~3.8M~4.3MTotalDx&TreatedPrevalence(eyes)2.4M8.4M11.1MTotalPrevalence(eyes)2.8M17.3M21.7M

26©2018GlaukosCorporationMIGSANDBEYONDPlatformDevelopment

27©2018GlaukosCorporationGlaukosPlatformPillarsiStentinject®iStent®SAiStentinfiniteTMiStentSupra®Restoringnatural,physiologicaloutflowiStent®•MIGSpioneerwithunrivaledportfolioofmicro-scaleglaucomadevices•Breakthroughabinternosurgicalinnovation•Deepexperienceanddemonstratedtrackrecordinmicro-engineeringdesign,assemblyandmanufacturability•RegulatorystrategyandmarketpositioningfocusedonlargepatientpopulationsandfullrangeofglaucomaprogressioniStentSA,iStentSupraandiStentinfinitearenotapprovedbytheFDA

28©2018GlaukosCorporationGlaukosPlatformPillarsiDoseTMTravoprostSustainedtherapypharmaceuticals•Leveraginguniqueexpertiseinmicro-mechanicaldesign,assemblyandfillingprocesses•Buildingseasonedoculardrugdeliveryteamof30+chemists,scientistsandengineersfromleadingpharmaceuticalcompanies•EnteredintopharmaceuticaldevelopmentagreementwithD.WesternTherapeuticsInstitutetoexplorenovelrhokinase(ROCK)inhibitorcompounds•UnderstandingnecessarydrugcharacteristicsandpredictabilityfordeliveryviaiDoseTMsystem•Small-moleculeAPIs,highpotency,lowaqueoussolubility•Receptordoesnotlosesensitivityduringlong-termdosing•Potentialforreducedsideeffectsvs.topicaldelivery•MolecularstructurechemicallystableovertimeiDoseTravoprostisanunapproveddrugandlimitedbyUSlawtoinvestigationaluseD.WesternDevelopmentAgreement

29©2018GlaukosCorporationGlaukos:KeyTakeawaysDeliveringnovelsurgicalandpharmaceuticalglaucomatherapy•ValidatingiDoseTMdrugdeliverysystemanddevelopingnewsustainedpharmaceuticalsplatform•ExtendingleadershipinMIGStreatmentclasswithindustry’smostcomprehensivesurgicaloffering•Deliveringsolidcadenceofmarket-expandingproductintroductionsfornext5+years•Addressingimportantunmetclinicalneedsinlargeandgrowingmarkets•Becomingmulti-facetedorganizationcapableoftransformingglaucomatherapy

30©2018GlaukosCorporation30